Natural Method for Clearing Cellular Debris Inspires Lupus Treatment
|
By LabMedica International staff writers Posted on 06 Mar 2012 |
Cells that die naturally generate a large amount of internal debris that can trigger the immune system to attack the body, leading to diseases such as lupus. Now, researchers report that an enzyme known to help keep a woman’s immune system from attacking a fetus also helps block development of these autoimmune diseases that target healthy tissues.
The study’s findings lead to toward new treatment approaches for autoimmune diseases, which are increasing in light of a germ-conscious society that regularly destroys many of the previously pervasive microbes that made the immune system more tolerant. “The basic premise of lupus is you have lost normal tolerance to yourself, your own proteins, and DNA,” said Dr. Tracy L. McGaha, Georgia Health Sciences University (GHSU; Augusta, USA) immunologist and corresponding author of the study published ahead of print February 21, 2012, in the journal Proceedings of the [US] National Academy of Sciences.
The investigators discovered that IDO, or indoleomine 2,3-dioxegenase, helps promote tolerance to debris generated by natural cell death and that when IDO is removed from the mixture, the debris triggers an immune response that can induce autoimmune disease. In mice genetically engineered to develop lupus, blocking IDO resulted in earlier, more aggressive disease. “This connects IDO and macrophages. It’s a newly described role for IDO in regulation of tolerance toward self,” Dr. McGaha remarked. Accordingly, increasing IDO production or its downstream effects might be a way to regain lost tolerance, he said.
The researchers assessed activity in the spleen; a hard-working immune organ that constantly filters blood. In a flawlessly organized defense, the entrance to the spleen is surrounded by immune cells that search the blood for viruses, bacteria, even fat and cholesterol floating by.
A neighboring subset of macrophages, which are basically scavengers, then capture and consume the undesirables, according to Dr. McGaha said. Fascinatingly, a lot of what macrophages consume is dead immune cells.
Macrophages also appear to help keep the peace by preventing the immune system from joining the fray. Dr. McGaha earlier found that if he destroyed macrophages, then fed the spleen dead cells, there was inflammation instead of calm. “That tells us there is something inherent in this subset of macrophages that is important for the suppressive process,” Dr. McGaha said referencing the study published in 2011 in the journal Blood.
The new study revealed that IDO is part of that “something.” Efficient elimination of cell debris while keeping nearby immune cells quiet is important because some debris is known to grab the attention of the immune system, According to Dr. McGaha. He noted that it is normal--and healthy--for damaged cells to become targets. “We are really interested in this process of normal cell debris removal because in lupus, it's thought to be one of the main drivers of inflammation,” he said.
The immune system has points of expansion and regulation where it decides whether or not to act. Knowing key points, such as IDO’s regulatory role, provides treatment targets that can interrupt a destructive cascade of immune activity, Dr. McGaha noted. Earlier research has shown evidence of self-attack is present many years before disease symptoms appear, he said.
Environmental hazards, such as a nasty sunburn, can be the first trigger of the abnormal immune response in diseases such as lupus. In healthy individuals, the immune system rises to the occasion of an infection then goes back to baseline. In autoimmune disease, patients tend not to return to normal levels.
GHSU’s Drs. Andrew Mellor and David Munn reported in 1998 in the journal Science that the fetus expresses IDO to help avoid rejection by the mother’s immune system. Following studies have shown tumors also use it and that it could help transplanted organs escape rejection. They suggested that Dr. McGaha evaluate IDO as a regulatory process used by macrophages.
Related Links:
Georgia Health Sciences University
The study’s findings lead to toward new treatment approaches for autoimmune diseases, which are increasing in light of a germ-conscious society that regularly destroys many of the previously pervasive microbes that made the immune system more tolerant. “The basic premise of lupus is you have lost normal tolerance to yourself, your own proteins, and DNA,” said Dr. Tracy L. McGaha, Georgia Health Sciences University (GHSU; Augusta, USA) immunologist and corresponding author of the study published ahead of print February 21, 2012, in the journal Proceedings of the [US] National Academy of Sciences.
The investigators discovered that IDO, or indoleomine 2,3-dioxegenase, helps promote tolerance to debris generated by natural cell death and that when IDO is removed from the mixture, the debris triggers an immune response that can induce autoimmune disease. In mice genetically engineered to develop lupus, blocking IDO resulted in earlier, more aggressive disease. “This connects IDO and macrophages. It’s a newly described role for IDO in regulation of tolerance toward self,” Dr. McGaha remarked. Accordingly, increasing IDO production or its downstream effects might be a way to regain lost tolerance, he said.
The researchers assessed activity in the spleen; a hard-working immune organ that constantly filters blood. In a flawlessly organized defense, the entrance to the spleen is surrounded by immune cells that search the blood for viruses, bacteria, even fat and cholesterol floating by.
A neighboring subset of macrophages, which are basically scavengers, then capture and consume the undesirables, according to Dr. McGaha said. Fascinatingly, a lot of what macrophages consume is dead immune cells.
Macrophages also appear to help keep the peace by preventing the immune system from joining the fray. Dr. McGaha earlier found that if he destroyed macrophages, then fed the spleen dead cells, there was inflammation instead of calm. “That tells us there is something inherent in this subset of macrophages that is important for the suppressive process,” Dr. McGaha said referencing the study published in 2011 in the journal Blood.
The new study revealed that IDO is part of that “something.” Efficient elimination of cell debris while keeping nearby immune cells quiet is important because some debris is known to grab the attention of the immune system, According to Dr. McGaha. He noted that it is normal--and healthy--for damaged cells to become targets. “We are really interested in this process of normal cell debris removal because in lupus, it's thought to be one of the main drivers of inflammation,” he said.
The immune system has points of expansion and regulation where it decides whether or not to act. Knowing key points, such as IDO’s regulatory role, provides treatment targets that can interrupt a destructive cascade of immune activity, Dr. McGaha noted. Earlier research has shown evidence of self-attack is present many years before disease symptoms appear, he said.
Environmental hazards, such as a nasty sunburn, can be the first trigger of the abnormal immune response in diseases such as lupus. In healthy individuals, the immune system rises to the occasion of an infection then goes back to baseline. In autoimmune disease, patients tend not to return to normal levels.
GHSU’s Drs. Andrew Mellor and David Munn reported in 1998 in the journal Science that the fetus expresses IDO to help avoid rejection by the mother’s immune system. Following studies have shown tumors also use it and that it could help transplanted organs escape rejection. They suggested that Dr. McGaha evaluate IDO as a regulatory process used by macrophages.
Related Links:
Georgia Health Sciences University
Latest BioResearch News
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
- Hidden Immune Gene Defect May Explain Kaposi Sarcoma Susceptibility
- Genetic Markers May Help Predict Amputation Risk in Peripheral Artery Disease
- Gene Signature Shows Promise for Depression Biomarker Testing
- AI-Driven Tumor Profiling Initiative Targets Precision Therapy Development
- Researchers Map Protein and Glycosylation Across 15 Human Body Fluids
Channels
Clinical Chemistry
view channel
Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
Confirming pediatric inflammatory bowel disease (IBD) often requires imaging, endoscopy, and histopathology, prolonging time to diagnosis. Reliable, noninvasive blood tests remain an unmet need in routine... Read more
Blood Test Detects More High-Risk Prostate Cancers Than PSA
Prostate cancer is one of the most common malignancies in men, and screening often struggles to distinguish indolent tumors from clinically significant disease. Prostate-specific antigen (PSA) testing... Read moreMolecular Diagnostics
view channel
Female-Specific RNA Biomarker May Help Explain Sex Differences in Immune Disease
Women show distinct susceptibility to infectious diseases and higher rates of autoimmune disorders, yet the molecular drivers remain unclear. This gap has limited sex-specific diagnostic and prognostic tools.... Read more
Genetic Marker Supports Anti-TNF Therapy Selection in Crohn’s Disease
Crohn’s disease, a major form of inflammatory bowel disease, is increasing across age groups and regions. Responses to current therapies vary widely, with only about half of patients benefiting, underscoring... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis
Conventional cytotoxicity assays often average responses across thousands of cells, obscuring how individual immune cells engage and kill tumor cells. For immunotherapy evaluation, the precise sequence... Read more
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read moreMicrobiology
view channel
Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella
Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more
Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read morePathology
view channel
Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
Reliable histologic subtyping guides therapy selection in oncology, yet diagnostic workflows grow more complex as whole-slide imaging and artificial intelligence (AI) expand. A persistent obstacle to clinical... Read more
Study Highlights Biomarker Testing Delays in Lung Cancer Care
Timely biomarker results are critical to match lung cancer patients with targeted therapies or immunotherapies, yet many clinical pathways still delay testing after biopsy. Ordering responsibility, reimbursement... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Aims to Broaden Access to NETosis-Linked Disease Testing
VolitionRx Limited (Henderson, NV, USA), a multinational epigenetics company, has announced a collaboration with Sysmex Corporation (Kobe, Japan), a global leader in in vitro diagnostics, to optimize Volition’s Nu.... Read more
Partnership Aims to Improve Transplant Monitoring Across Care Continuum
Allograft rejection and chronic graft dysfunction remain major challenges in solid organ transplantation, requiring careful immunologic matching and long-term surveillance. Fragmented pre- and post-transplant... Read more
QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more








